Table 1.
Study characteristics of RCT studies with MIGS devices
| Study | Study design | IOP-lowering intervention (n) | Subgroup | Intervention | Mean baseline IOP (mmHg; ± SD) | Country | Longest follow-up |
|---|---|---|---|---|---|---|---|
| iStent® | |||||||
| Craven et al. [33] | Prospective, multicenter | MIGS (n = 98) | iStent | Single trabecular micro-bypass stent with concomitant cataract surgery | 25.4 ± 3.6 | USA | 24 months |
| Cataract surgery alone (n = 101) | Phacoemulsification | Cataract surgery | 25.2 ± 3.6 | ||||
| Fea et al. [31] | Prospective, double-masked | Cataract surgery with MIGS (n = 12) | iStent | Phacoemulsification with iStent® implantation (combined group) | 17.9 ± 2.6 | Italy | 15 months |
| Cataract surgery (n = 24) | Phacoemulsification | Phacoemulsification alone (control group) | 17.3 ± 3.0 | ||||
| Fea et al. [34] | Prospective unmasked randomized evaluation | MIGS (n = 94) | iStent (inject) × 2 stents | iStent® inject device | 25.2 ± 1.4 | Italy, Spain, Poland, Germany, UK, and Armenia | 12 months |
| Medication (n = 98) | Meds fixed combination of latanoprost/timolol | Two medications | 24.8 ± 1.7 | ||||
| Fea et al. [35] | Prospective | MIGS (n = 10) | iStent micro-bypass | iStent® implantation and cataract surgery (combined group) | 17.8 ± 2.7 | Italy | 48 months |
| Cataract surgery alone (n = 14) | Phacoemulsification | Cataract surgery alone (control group) | 16.7 ± 3.0 | ||||
| Fernández-Barrientos et al. [32] | Prospective | Cataract surgery with MIGS (n = 17) | iStent × 2 | iStents and cataract surgery | 24.2 ± 1.8 | Spain | 12 months |
| Cataract surgery alone (n = 16) | Phacoemulsification | Cataract surgery alone | 23.6 ± 1.5 | ||||
| Katz et al. [36] | Prospective | MIGS (n = 38) | iStent × 1 | One trabecular microbypass stent | 19.8 ± 1.3 | USA | 18 months |
| MIGS (n = 41) | iStent × 2 | Two stents | 20.1 ± 1.6 | ||||
| MIGS (n = 40) | iStent × 3 | Three stents | 20.4 ± 1.8 | ||||
| Vold et al. [37] | Cohort study | MIGS (n = 54) | iStent × 2 | Two trabecular bypass stents | 25.5 ± 2.5 | Armenia | 36 months |
| Medication (n = 47) | Topical travoprost | Topical travoprost | 25.1 ± 4.6 | ||||
| Hydrus® Micro-Stent | |||||||
| Pfeiffer et al. [38] | Prospective, multicenter, single-masked | Cataract surgery with MIGS (n = 50) | Hydrus Micro-Stent plus Phacoemulsification | Hydrus Micro-Stent and cataract surgery group | 18.9 ± 3.3 | Germany, Spain, Netherlands, and Italy | 24 months |
| Cataract surgery alone (n = 50) | Phacoemulsification | Cataract surgery group | 18.6 ± 3.8 | ||||
| CyPass® Micro-Stent | |||||||
| Vold et al. [39] | Prospective, multicenter | MIGS (n = 54) | CyPass Micro-Stent | Micro-stent implantation via an ab interno approach | 26.3 ± 4.4 | USA | 24 months |
| Cataract surgery (n = 47) | Phacoemulsification | Phacoemulsification alone (control group) | 26.6 ± 4.2 | ||||